Prodigiosin Down-regulates SKP2 to Induce P27(KIP1) Stabilization and Antiproliferation in Human Lung Adenocarcinoma Cells

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2012 Mar 1

PMID 22372491

Citations 23

Authors

Hsin-Ying Hsieh

Jeng-Jer Shieh

Chun-Jung Chen

Mu-Yun Pan

Shu-Yi Yang

Shin-Chang Lin

Jo-Shu Chang

Alan Yueh-Luen Lee

Chia-Che Chang

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: High levels of SKP2 are a poor prognostic factor in multiple human cancers and mostly correlate with low p27(KIP1) levels. Prodigiosin is a bacterial tripyrrole pigment with strong pro-apoptotic activity. Induction of cell cycle blockade underlies one of its anticancer actions but the mechanisms involved are unclear. The aim of this study was to explore the role of the SKP2-p27(KIP1) axis in prodigiosin's cytostatic effect on human lung adenocarcinoma cells.

Experimental Approach: Prodigiosin's effects on cell cycle progression and long-term cell proliferation of human lung adenocarcinoma cells were characterized by flow cytometry and colony formation assay, respectively. Real-time RT-PCR and promoter activity analyses were performed for assessing transcriptional control, while cycloheximide chase analysis evaluated protein stability. Immunoblotting was employed for mechanistic study.

Key Results: Prodigiosin increased p27(KIP1) expression mainly by stabilizing p27(KIP1) through transcriptional repression of SKP2. Importantly, SKP2 overexpression or p27(KIP1) depletion restored the colony forming capacity of prodigiosin-treated cells. Furthermore, prodigiosin induced PKB dephosphorylation, leading to PKB inhibition as revealed by decreased serine 9 phosphorylation of GSK-3β. Constitutive PKB activation reduced prodigiosin-induced SKP2 repression. Prodigiosin also down-regulated E2F1 (mediates PI3K/PKB-induced SKP2 transcription), but E2F1 overexpression failed to restore SKP2 expression in prodigiosin-treated cells.

Conclusions And Implications: Transcriptional repression of SKP2 and the consequent accumulation of p27(KIP1) are essential for prodigiosin's antiproliferative action. Mechanistically, prodigiosin induces PKB inhibition to down-regulate SKP2 in a GSK-3β- and E2F1-independent manner. Our findings further implicate the potential for developing prodigiosin as a novel class of SKP2-targeting anticancer agent.

Citing Articles

Evaluation of the Combinatory Anticancer Effect of Chemotherapeutic Compounds and Prodigiosin against HCT-116, LoVo, and A549 Cell lines.

Elghali F, Msalbi D, Frikha F, Alonazi M, Sahli E, Hakim B ACS Omega. 2024; 9(49):48112-48124.

PMID: 39676943 PMC: 11635512. DOI: 10.1021/acsomega.4c04760.

Rational Design of Nanomedicine for Placental Disorders: Birthing a New Era in Women's Reproductive Health.

Geisler H, Safford H, Mitchell M Small. 2023; 20(41):e2300852.

PMID: 37191231 PMC: 10651803. DOI: 10.1002/smll.202300852.

Identification of Novel Protein Targets of Prodigiosin for Breast Cancer Using Inverse Virtual Screening Methods.

Paul T, Bhardwaj P, Mondal A, Bandyopadhyay T, Mahata N, Bhunia B Appl Biochem Biotechnol. 2023; 195(12):7236-7254.

PMID: 36988846 DOI: 10.1007/s12010-023-04426-9.

Rise of the natural red pigment 'prodigiosin' as an immunomodulator in cancer.

Anwar M, Albanese C, Hamdy N, Sultan A Cancer Cell Int. 2022; 22(1):419.

PMID: 36577970 PMC: 9798661. DOI: 10.1186/s12935-022-02815-4.

Prodigiosin inhibits the proliferation of glioblastoma by regulating the KIAA1524/PP2A signaling pathway.

Zhao W, Gao D, Ning L, Jiang Y, Li Z, Huang B Sci Rep. 2022; 12(1):18527.

PMID: 36323805 PMC: 9630538. DOI: 10.1038/s41598-022-23186-w.

References

Bretones G, Acosta J, Caraballo J, Ferrandiz N, Teresa Gomez-Casares M, Albajar M . SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells. J Biol Chem. 2011; 286(11):9815-25. PMC: 3059036. DOI: 10.1074/jbc.M110.165977. View

Ohtani K, DeGregori J, Nevins J . Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci U S A. 1995; 92(26):12146-50. PMC: 40313. DOI: 10.1073/pnas.92.26.12146. View

Soto-Cerrato V, Vinals F, Lambert J, Kelly J, Perez-Tomas R . Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3beta activity in human breast cancer cells. Mol Cancer Ther. 2007; 6(1):362-9. DOI: 10.1158/1535-7163.MCT-06-0266. View

Wang H, Bauzon F, Ji P, Xu X, Sun D, Locker J . Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice. Nat Genet. 2009; 42(1):83-8. PMC: 2990528. DOI: 10.1038/ng.498. View

Cataldo V, Gibbons D, Perez-Soler R, Quintas-Cardama A . Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med. 2011; 364(10):947-55. DOI: 10.1056/NEJMct0807960. View

Zuo T, Liu R, Zhang H, Chang X, Liu Y, Wang L . FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest. 2007; 117(12):3765-73. PMC: 2075479. DOI: 10.1172/JCI32538. View

Nakayama K, Nagahama H, Minamishima Y, Miyake S, Ishida N, Hatakeyama S . Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell. 2004; 6(5):661-72. DOI: 10.1016/s1534-5807(04)00131-5. View

Uddin S, Ahmed M, Bavi P, El-Sayed R, Al-Sanea N, Abduljabbar A . Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. Cancer Res. 2008; 68(9):3379-88. DOI: 10.1158/0008-5472.CAN-07-6109. View

Pang P, Lin Y, Lee Y, Hou H, Hsu S, Juan S . Molecular mechanisms of p21 and p27 induction by 3-methylcholanthrene, an aryl-hydrocarbon receptor agonist, involved in antiproliferation of human umbilical vascular endothelial cells. J Cell Physiol. 2007; 215(1):161-71. DOI: 10.1002/jcp.21299. View

10.

Soto-Cerrato V, Vinals F, Lambert J, Perez-Tomas R . The anticancer agent prodigiosin induces p21WAF1/CIP1 expression via transforming growth factor-beta receptor pathway. Biochem Pharmacol. 2007; 74(9):1340-9. DOI: 10.1016/j.bcp.2007.07.016. View

11.

Chu I, Hengst L, Slingerland J . The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008; 8(4):253-67. DOI: 10.1038/nrc2347. View

12.

Niculescu 3rd A, Chen X, Smeets M, Hengst L, Prives C, Reed S . Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol. 1998; 18(1):629-43. PMC: 121530. DOI: 10.1128/MCB.18.1.629. View

13.

Ramalingam S, Owonikoko T, Khuri F . Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin. 2011; 61(2):91-112. DOI: 10.3322/caac.20102. View

14.

Chang C, Chen W, Ho T, Wu H, Wei Y . Development of natural anti-tumor drugs by microorganisms. J Biosci Bioeng. 2011; 111(5):501-11. DOI: 10.1016/j.jbiosc.2010.12.026. View

15.

Liu Y, Perdreau S, Chatterjee P, Wang L, Kuan S, Duensing A . Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis. Cancer Res. 2008; 68(21):9015-23. DOI: 10.1158/0008-5472.CAN-08-1935. View

16.

Zhang L, Wang C . F-box protein Skp2: a novel transcriptional target of E2F. Oncogene. 2005; 25(18):2615-27. PMC: 1513044. DOI: 10.1038/sj.onc.1209286. View

17.

Ling Y, Li T, Yuan Z, Haigentz Jr M, Weber T, Perez-Soler R . Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell.... Mol Pharmacol. 2007; 72(2):248-58. DOI: 10.1124/mol.107.034827. View

18.

Sonoda H, Inoue H, Ogawa K, Utsunomiya T, Masuda T, Mori M . Significance of skp2 expression in primary breast cancer. Clin Cancer Res. 2006; 12(4):1215-20. DOI: 10.1158/1078-0432.CCR-05-1709. View

19.

Uddin S, Ahmed M, Hussain A, Jehan Z, Al-Dayel F, Munkarah A . Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer. Lab Invest. 2009; 89(10):1115-27. DOI: 10.1038/labinvest.2009.75. View

20.

Yoshida T, Zhang G, Haura E . Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. Biochem Pharmacol. 2010; 80(5):613-23. DOI: 10.1016/j.bcp.2010.05.014. View